|
gptkbp:instance_of
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:activities
|
topoisomerase II inhibitor
topoisomerase inhibitor
|
|
gptkbp:appointed_by
|
oral capsule
intravenous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Ve_Pesid
|
|
gptkbp:can_be_used_with
|
gptkb:cisplatin
gptkb:carboplatin
gptkb:doxorubicin
gptkb:ifosfamide
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
hypersensitivity to etoposide
severe bone marrow suppression
|
|
gptkbp:developed_by
|
gptkb:podophyllotoxin
|
|
gptkbp:discovered_by
|
1970s
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
etoposide
|
|
gptkbp:ingredients
|
C21 H21 O9
|
|
gptkbp:interacts_with
|
gptkb:warfarin
live vaccines
other chemotherapy agents
|
|
gptkbp:is_atype_of
|
L01 B B01
|
|
gptkbp:is_available_on
|
oral capsule
lyophilized powder
injectable solution
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
treating cancer
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:pharmacokinetics
|
metabolized in liver
bioavailability 50% to 70%
half Life 4 to 11 hours
|
|
gptkbp:side_effect
|
nausea
vomiting
hair loss
hypotension
bone marrow suppression
low blood cell counts
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:treatment
|
gptkb:healthcare_organization
gptkb:non-Hodgkin_lymphoma
gptkb:Wilms_tumor
gptkb:neuroblastoma
small cell lung cancer
|
|
gptkbp:type_of
|
33419-42-0
|
|
gptkbp:bfsParent
|
gptkb:embryonal_carcinoma
|
|
gptkbp:bfsLayer
|
4
|